Skip to content
PubMed This is a summary of 31 peer-reviewed journal articles Updated
Immunology · Late-Onset Combined Immunodeficiency due to ICOSLG Deficiency

Late-Onset Combined Immunodeficiency due to ICOSL Deficiency: A Patient Guide

At a Glance

Late-onset combined immunodeficiency from ICOSLG deficiency is an exceptionally rare inherited disorder that can cause recurrent lung infections, persistent HPV or HSV infections, and low neutrophils. Care is individualized, often including antibody replacement and preventive antibiotics.

Please note: Because published human experience is extremely limited, this guide is based primarily on one deeply characterized human case. It does not establish a universal standard protocol; treatment and surveillance decisions must be individualized with your specialist based on your immune testing and infection history.

Late-Onset Combined Immunodeficiency due to ICOSLG deficiency is an exceptionally rare genetic condition that fundamentally changes how your immune system communicates. It is classified as an inborn error of immunity, which means it is a “built-in” part of your biology caused by inheriting two non-working (pathogenic) copies of a specific gene from your parents—a pattern known as autosomal recessive inheritance [1]. Because this condition is so rare that it is currently defined in the medical literature primarily by a single, deeply characterized human case, you and your care team are navigating a frontier of medical science where every piece of information is vital [2].

At its core, this condition is a breakdown in the “conversation” between your T cells (the generals of the immune system) and your B cells (the antibody factories). Normally, a protein called ICOSL acts as a ligand (bridge or a key) on the surface of some cells, allowing them to coordinate a sophisticated defense. In this deficiency, a genetic variant—most notably the p.N219K variant—prevents this protein from ever reaching the cell surface [1]. Instead of acting as a signal to other cells, the protein remains stuck inside your cells, impairing the immune system’s ability to form certain switched-memory B cells and specific antibody responses to fight off germs effectively [3].

In the reported patient, this biological silence led to two main types of health challenges. The first was a pattern of recurrent respiratory infections, such as sinusitis, bronchitis, or pneumonia, which occur because the body cannot produce enough high-quality antibodies. The second was a unique vulnerability to DNA viruses that affect the skin and mucosal surfaces. This manifested as persistent and severe infections like HPV (warts) or HSV (cold sores), which may not respond to standard treatments as expected [1][2]. Additionally, the patient experienced neutropenia, a low count of the “first responder” white blood cells that would normally rush to the site of an infection [1].

Because there are so few documented cases, the standard of care is highly individualized and focuses on supportive measures to fill the gaps in your immune defense. Depending on your history and labs, this may involve Immunoglobulin Replacement Therapy (IgRT) to provide the antibodies your body cannot make on its own, alongside preventive antibiotics to protect your lungs from long-term damage [3]. Unlike some other immune disorders, more intensive treatments like stem cell transplants are not currently considered standard for this specific condition, partly due to biological concerns regarding the missing protein on blood vessel linings [1].

Navigating a diagnosis this rare requires a partnership with a specialist in inborn errors of immunity who can tailor your surveillance and treatment to your specific symptoms. While the rarity of the condition means there is still much to learn about the long-term outlook, a proactive approach to monitoring your lung health and skin allows you to manage the condition effectively. By working with a specialized center, you ensure that your care is grounded in the latest research and that you have a team capable of responding to the unique ways this condition behaves in your body [1][3].

Common questions in this guide

What is late-onset combined immunodeficiency caused by ICOSLG deficiency?
It is an exceptionally rare inherited immune disorder caused by harmful changes in both copies of the ICOSLG gene. The missing or misplaced ICOSL protein disrupts communication between T cells and B cells, which can weaken antibody responses and increase susceptibility to infections.
What infections can occur with ICOSLG deficiency?
Reported problems include repeated respiratory infections such as sinusitis, bronchitis, and pneumonia. The reported patient also had persistent or severe HPV infections causing warts and HSV infections such as cold sores, along with neutropenia.
How is ICOSLG deficiency inherited?
The condition follows an autosomal recessive pattern, meaning a person inherits two pathogenic copies of the ICOSLG gene, usually one from each parent. The p.N219K variant has been reported in a deeply characterized patient, but a person's exact variant should be confirmed by their specialist.
How is late-onset combined immunodeficiency due to ICOSLG deficiency treated?
Treatment is individualized because very few human cases have been described. Care may include immunoglobulin replacement therapy to provide needed antibodies, preventive antibiotics to reduce infection risk, and monitoring of lung and skin health; stem cell transplantation is not currently standard for this specific condition.
Which specialists should manage ICOSLG deficiency?
Care should be coordinated by a specialist in inborn errors of immunity or clinical immunology. Depending on symptoms, the team may also include dermatology and infectious disease specialists to monitor skin, mucosal, viral, and respiratory complications.

Get notified when new evidence is published on Late-onset combined immunodeficiency due to ICOSL deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (3)
  1. 1

    Loss of human ICOSL results in combined immunodeficiency.

    Roussel L, Landekic M, Golizeh M, et al.

    The Journal of experimental medicine 2018; (215(12)):3151-3164 doi:10.1084/jem.20180668.

    PMID: 30498080
  2. 2

    ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency.

    Roussel L, Vinh DC

    Current opinion in immunology 2021; (72()):21-26 doi:10.1016/j.coi.2021.03.001.

    PMID: 33756276
  3. 3

    14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency.

    Schepp J, Chou J, Skrabl-Baumgartner A, et al.

    Frontiers in immunology 2017; (8()):964 doi:10.3389/fimmu.2017.00964.

    PMID: 28861081

This page is for informational purposes only and does not constitute medical advice. Because ICOSLG deficiency is exceptionally rare, use this information to support—not replace—individual guidance from an inborn-errors-of-immunity specialist.